Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2017 /
Added ibrutinib in first-line CLL treatment

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 1947

Dr Nitin Jain - MD Anderson Cancer Center, Houston, USA

Dr Jain speaks with ecancer at the ASH 2017 annual meeting about adding ibrutinib to frontline chemotherapy for CLL patients with mIGHV and without TP53 aberrations.

The trial combination came with an increase in grade 3/4 toxicities which he describes as manageable once identified, and one death attributed to non-trial medication.

Overall, Dr Jain looks forward to further enrollment of trial participants.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Categories:

· ASH 2017

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation